SLRN vs. TRDA, OCS, ANL, FULC, LXRX, ANNX, LRMR, TVTX, TBPH, and CRBP
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Entrada Therapeutics (TRDA), Oculis (OCS), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Lexicon Pharmaceuticals (LXRX), Annexon (ANNX), Larimar Therapeutics (LRMR), Travere Therapeutics (TVTX), Theravance Biopharma (TBPH), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, Entrada Therapeutics had 1 more articles in the media than Acelyrin. MarketBeat recorded 16 mentions for Entrada Therapeutics and 15 mentions for Acelyrin. Entrada Therapeutics' average media sentiment score of 1.03 beat Acelyrin's score of 0.39 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
Acelyrin presently has a consensus price target of $21.67, indicating a potential upside of 356.14%. Entrada Therapeutics has a consensus price target of $21.00, indicating a potential upside of 44.93%. Given Acelyrin's higher probable upside, research analysts clearly believe Acelyrin is more favorable than Entrada Therapeutics.
Entrada Therapeutics has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
87.3% of Acelyrin shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 13.6% of Acelyrin shares are held by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Entrada Therapeutics has a net margin of 14.42% compared to Acelyrin's net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat Acelyrin's return on equity.
Acelyrin and Entrada Therapeutics both received 11 outperform votes by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 61.11% of users gave Acelyrin an outperform vote.
Summary
Entrada Therapeutics beats Acelyrin on 11 of the 15 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
